Diabetes mellitus and severe mental illness: mechanisms and clinical implications. (Q38274901)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25445848%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

review article

1 reference

title

Diabetes mellitus and severe mental illness: mechanisms and clinical implications (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25445848%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25445848%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Alex J. Mitchell

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25445848%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Richard I G Holt

series ordinal

1

1 reference

1 September 2017

2 December 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25445848%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Endocrinology

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25445848%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25445848%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

79-89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25445848%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25445848%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrendo.2014.203

23 February 2020

exact match

0 references

cites work

Twenty-five year mortality of a community cohort with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Schizophrenia: a concise overview of incidence, prevalence, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

A Systematic Review of Mortality in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Antipsychotic drugs and diabetes--an application of the Austin Bradford Hill criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Association between antipsychotic drugs and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Diabetes and schizophrenia 2005: are we any closer to understanding the link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Obesity, serious mental illness and antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-South Ontario (DiSCO) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Risk of acute complications of diabetes among people with schizophrenia in Ontario, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Receipt of diabetes services by insured adults with and without claims for mental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Long-term mortality of persons with severe mental illness and diabetes: a population-based cohort study in Denmark.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Parental history of type 2 diabetes in patients with nonaffective psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Biological insights from 108 schizophrenia-associated genetic loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Schizophrenia as a GSK-3 dysregulation disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Lack of association between a functional variant of the BRCA-1 related associated protein (BRAP) gene and ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Tyrosine hydroxylase gene microsatellite polymorphism associated with insulin resistance in depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Genetics of antipsychotic-induced weight gain: update and current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Is birth weight related to later glucose and insulin metabolism?--A systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Birth weight and the risk of depressive disorder in late life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Early life predictors of the physiological stress response later in life

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Schizophrenia after prenatal famine. Further evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Association of psychiatric illness and obesity, physical inactivity, and smoking among a national sample of veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Vitamin D and type 2 diabetes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Serum vitamin D levels in relation to schizophrenia: a systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Clinical review: Effect of vitamin D3 supplementation on improving glucose homeostasis and preventing diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Environmental correlates of physical activity and dietary behaviours among young people: a systematic review of reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Identifying aspects of neighbourhood deprivation associated with increased incidence of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Clock genes at the heart of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Sex hormones in psychotic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Neurological complications of psychiatric drugs: clinical features and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Adverse effects of atypical antipsychotics : differential risk and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Diabetes risk potentially underestimated in youth and children receiving antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Quetiapine treatment in youth is associated with decreased insulin secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Molecular pathophysiology of metabolic effects of antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Almost all antipsychotics result in weight gain: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiolog

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

The heart of the matter: cardiometabolic care in youth with psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Screening for metabolic syndrome in older patients with severe mental illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Receipt of preventive medical care and medical screening for patients with mental illness: a comparative analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Quality of preventive medical care for patients with mental disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Screening for cardiovascular risk in patients with severe mental illness in primary care: a comparison with patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Screening for metabolic risk among patients with severe mental illness and diabetes: a national comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

A UK audit of screening for the metabolic side effects of antipsychotics in community patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Dietary improvement in people with schizophrenia: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Intentional weight loss in overweight and obese patients with severe mental illness: 8-year experience of a behavioral treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Identifying risk and preventing progression to Type 2 diabetes in vulnerable and disadvantaged adults: a pragmatic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Standards of medical care in diabetes--2014

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

The effects of antipsychotic switching on diabetes in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Association of dopamine D2 receptor polymorphisms Ser311Cys and TaqIA with obesity or type 2 diabetes mellitus in Pima Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Immunological characteristics of diabetes in schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Antipsychotics and diabetes: an age-related association

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Recent advances in the molecular genetics of type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Birth weight, stress, and symptoms of depression in adolescence: evidence of fetal programming in a national Canadian cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Fetal growth restriction and the development of major depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

The unhealthy lifestyle of people with schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Diet, diabetes and schizophrenia: review and hypothesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Schizophrenia: a multisystem disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Antipsychotics and the risk of type 2 diabetes mellitus in children and youth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

Adherence to Diabetes Medication in Individuals with Schizophrenia: A Systematic Review of Rates and Determinants of Adherence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.203

The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders

31 March 2020

1 reference

12 December 2020

Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials.

1 reference

12 December 2020

Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program

1 reference

12 December 2020

Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis

1 reference

12 December 2020

Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2014.203

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25445848%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference